hVIVO plc (LON: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed an £11.5 million contract with an existing top-tier global pharmaceutical client to test its antiviral candidate using hVIVO’s Respiratory Syncytial Virus (“RSV”) Human Challenge Study Model.
The Phase 2a randomised, double-blinded placebo-controlled human challenge trial will evaluate the safety, pharmacokinetics and antiviral activity of the drug candidate. hVIVO will leverage its in-house volunteer recruitment arm, FluCamp, to enrol healthy volunteers into the study. The study is scheduled to commence in H2 2025 at hVIVO’s state-of-the-art quarantine facilities in Canary Wharf, with revenue expected to be recognised across 2025 and 2026.
This repeat contract with an existing client highlights the value that global pharma place on hVIVO’s human challenge trials. hVIVO’s trials offer a time-efficient and cost-effective way to generate early human efficacy data and inform later stage trial design, which can accelerate the path to market for new therapies.
